Latent tuberculosis infection in patients with end-stage kidney disease. research hub

Comparison of treatment completion rates with three short-course rifamycin-based regimens (three months of daily isoniazid plus rifampicin [3HR], three months of once-weekly isoniazid plus rifapentine [3HP], and four months of daily rifampicin [4R]) for treatment of latent tuberculosis infection in patients with end-stage kidney disease: A randomised controlled clinical trial (RIFAKiD-TB Trial)

This study is looking at the best ways to treat a common but silent infection called latent TB in people who also have serious kidney disease. It compares three different medicine plans to see which one people are most likely to finish, as finishing the treatment is very important.